RiverVest Venture Partners United States

RiverVest Venture Partners is a venture capital firm that was founded in 2000 and is based in St. Louis, Missouri with additional office in Cleveland, Ohio. The firm currently has managed over $208 million of total assets. RiverVest has raised two investment funds with total committed capital of $165 million since inception. The recent fund closed at $75 million. RiverVest typically makes equity investments into global companies, and has no specific geographic preferences. The firm will consider making investments at all the stages, and focuses on investments in seed, early-stage and select later-stage companies. The typical investment size is around $6 million, though the firm can invest more or less, depending on the opportunity. 

RiverVest is extremely opportunistic when it comes to investments in the life sciences space; with that being said RiverVests specified sectors and sub sectors of interest may or may not be an area in which RiverVest is currently looking to allocate capital to. The firm invests in companies in the biotech therapeutics and diagnostics, as well the medical technology space. 

Some of the firms investments have included companies developing biotech therapeutics and diagnostics targeting diseases of the blood and blood forming organs, neoplasms, cancer, and oncology, skin and subcutaneous tissue, cardiovascular diseases, diseases of the ear, and infectious diseases. The firm has also invested in companies developing anti-body based therapeutics. The firm has also invested in firms developing medical technologies such as therapeutic radiation devices, active implantable devices, non active implantable devices, hospital hardware, and imaging devices.

Year Founded
2000
Investor Type
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Karen Spilizewski
VP 

Safeguard Scientifics

Safeguard Scientifics is a publicly traded capital deployment firm founded in 1953 and is based in Wayne PA. The firm makes deployments from an evergreen fund and is actively seeking new investments in the healthcare sector. Initial equity placements are typically of $5-1m with the potential for a total allocation of $2-25m over the life of an investment. The firm focuses on North America with a concentration in the Mid-Atlantic and San Francisco Bay Area regions. Deployments are made at a range of stages from early-stage to growth expansion and recapitalization. Safeguard Scientifics prefers to be a sizable minority investor.
Gary Kurtzman
Managing Director 

Sand Hill Angels

Sand Hill Angels is an angel group that was founded in 2 and is headquartered in Sunnyvale California. The group focuses on investments in early-stage (from seed to series C) companies in the Life Sciences IT Internet and Clean Tech sectors. The group prefers to make equity and convertible notes investments and the typical investment size ranges from $.1million to $.5million. The group will consider syndicating with other investors for larger investments. The group will consider companies across the US.
Stephen Pollitt
Board Member Membership Chair 

Symbient Product Development United States

Rapid Development of Injection Molded Medical Devices
From Concept Through Transfer-to-Manufacturing

Symbient specializes in engineering research and development, prototyping and design-for-manufacturing of innovative medical devices that use injection molded components. Our highly experienced team consists of mechanical and biomedical engineers, industrial designers, machinists and molding technicians. They leverage our in-house rapid prototyping, and prototype tooling fabrication and injection molding to create proven, manufacturable designs with unmatched speed, efficiency and precision. These designs make up our deep portfolio of over 300 successful devices that have collectively generated hundreds of millions of dollars. They include FDA Class I, II and III devices, developed under our ISO 13485 certified quality management system.

 

Our Services Include:

  • Concept Development
  • Development Engineering
  • Design-for-Manufacturing
  • Industrial Design
  • Project Rescue
  • Design Control per IOS 13485
  • Finite Element Analysis (FEA)
  • Design Verification Testing
  • Test Method Development
  • Transfer to Manufacturing

 

Our In-House Capabilities and Expertise Include:

  • Stereolithography (SLA) Prototyping
  • CNC Machining / Fabrication
  • Prototype Mold Fabrication
  • Prototype Injection Molding of Devices for Testing, Trials and Studies
  • Liquid Injection Molded (LIM) Silicone Prototype Molding
  • Product Reliability Testing
  • Plastics Assembly Expertise: Ultrasonic and Laser Welding, Heat Sealing, Pressure Sensitive Adhesives, Swaging, Snap Fits, Press Fits, Interlocks.
  • Speed: Prototype Molds in as little as 1 week and Modifications in as little as 1 Day
  • Material Selection Expertise, Research and Testing to Ensure All Product Requirements Are Met.

 

Our Portfolio Includes:

  • Diagnostics / Molecular Diagnostics
  • Sample collection / preparation
  • Life Sciences / Microfluidics
  • OTC Consumer products
  • Respiratory
  • Surgical devices and clinical tools
  • Drug Delivery

 

Year Founded
2004
Unique Capabilities

Our Services Include:

  • Concept Development
  • Development Engineering
  • Design-for-Manufacturing
  • Industrial Design
  • Project Rescue
  • Design Control per IOS 13485
  • Finite Element Analysis (FEA)
  • Design Verification Testing
  • Test Method Development
  • Transfer to Manufacturing

 

Our In-House Capabilities and Expertise Include:

  • Stereolithography (SLA) Prototyping
  • CNC Machining / Fabrication
  • Prototype Mold Fabrication
  • Prototype Injection Molding of Devices for Testing, Trials and Studies
  • Liquid Injection Molded (LIM) Silicone Prototype Molding
  • Product Reliability Testing
  • Plastics Assembly Expertise: Ultrasonic and Laser Welding, Heat Sealing, Pressure Sensitive Adhesives, Swaging, Snap Fits, Press Fits, Interlocks.
  • Speed: Prototype Molds in as little as 1 week and Modifications in as little as 1 Day
  • Material Selection Expertise, Research and Testing to Ensure All Product Requirements Are Met.
Lisa Coyne
Business Development Manager 
Luke Helm
Director of Business Development 

Tech Coast Angels

Founded in 1997, Tech Coast Angels is the largest angel investor group in the United States. Its members provide funding and guidance to more early-stage high-growth companies in Southern California than any other investment group. TCA members invest in companies in a wide range of industries including life sciences, biotech and health IT. TCA has more than 325 members including its venture capital affiliates in five networks in Los Angeles Orange County San Diego Westlake/Santa Barbara and the Inland Empire. The organization will finance on an opportunistic basis as long as substantial disruptive market opportunities exists. The firm has historically invested in Biotech Therapeutics & Diagnostics, Biotechnology R&D Services, Biotechnology Other, Medical Technology companies with sub sectors of Anti-Infectives, Bioinformatics, CRO (Contract Research Organization), Diagnostic Instrumentation, Diagnostic Services, Drug Delivery, Food, Industrial Biotechnology, Small Molecules, Small Molecule Therapeutics, Wound Care and indications including Diseases of the Nervous System, Infectious and Parasitic Diseases, Neoplasms/Cancer/Oncology, Respiratory.

Websites:
www.greenwingsbiomedical.com
techcoastangels.com

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Richard Koffler
Member 

Twin Cities Angels Fund II, LLC United States

Twin Cities Angels is an angel group that was founded in 2006 that is based in Minnesota. The group has raised two funds that are The Twin Cities Angels Fund I and II. The second fund is currently looking to invest in emerging companies. The group typically provides seed and venture capital ranging from $ 25.000 to $2 million to life science companies. The group plans to invest in 4 to 6 companies per year. Twin Cities Angels seeks to invest in companies based in the Twin Cities Area of Minneapolis/St. Paul, the state of Minnesota and within a reasonable distance, such as Western Wisconsin, Northern Iowa, and Eastern Dakotas.

Year Founded
2006
Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
John Alexander
Chairman & Founder 

TYLT Lab

TYLT Lab was founded in 213 and has offices in Santa Monica CA and in Hong Kong. TYLT Lab invests across a variety of sectors including biotech and medical technology and will be raising a second fund in 215. TYLT Lab typically invests $5-$1 million and prefers to invest in seed or Series A rounds. The firm makes up to 12 allocations per year and is interested in opportunities globally, companies developing products that can impact healthcare delivery in emerging markets such as China or India are of particular interest.
Gerard Casale
Managing Director 

Venture Valuation Switzerland

Venture Valuation specializes in independent assessments and valuations of companies in high-growth markets, such as biotechnology, life sciences and medical technology. Further more, the company runs the global Biotech Database (www.biotechgate.com) as a subscription service as well as a white label solution for clients like BIOTECanada, BioCom San Diego, Maryland, HTX, OneNucleus, Swiss Biotech Association, SwedenBIO, Medicon Valley and many more.

Company Valuation:
----------------------------
The Company Valuation Reports include a thorough assessment of the company by experienced professionals with expertise in the relevant fields as well as the following elements:

  • summary of key risk parameters and strengths of the company
  • outline of the crucial factors and value drivers for growth and further strategic development
  • assessment of the management, market, science, technology and products
  • analysis of the company’s business model and the company’s competitive environment
  • detailed calculation of the company’s financial value, using appropriate valuation methods


Product Valuation:
--------------------------
Venture Valuation offers detailed Product Valuation Reports of pre-clinical and clinical products in development that can serve as a basis for negotiations or to structure different deal scenarios. The Product Valuation includes:

  • detailed analysis of development costs, time lines, patient population, competing products, pricing and product life cycle
  • industry gold standard rNPV valuation methodology based on indication-specific attrition rates and the development stage
  • scenario and sensitivity analyses
  • analysis of the current value, and forecasts of the future value following the successful completion of key development milestones


As an “add on” module and based on Venture Valuation’s deal database within Biotechgate, benchmarking deals can also be included to provide the client with a differentiated negotiation basis and comparable information.

Licensing Candidate Search:
----------------------------------------
Based on unique valuation and industry expertise, and leveraging access to the proprietary client and products database, Venture Valuation offers individual, tailor-made solutions to customers. The Licensing Candidate Search includes licensing partner identification and an evaluation of potential products for licensing.

Biotechgate Database:
-------------------------------
Venture Valuation has developed and maintains the Biotechgate Database (biotechgate.com). Biotechgate is a global life sciences directory established in 2004 based on the needs of investors and company managers to access accurate and up-to-date industry intelligence.

The database contains over 30’000 company profiles. For Business Development managers, the database provides benchmarking licensing opportunities as well as detailed financial information covering more than 1’600 licensing deals involving therapeutic products and over 5’000 financing rounds.

Dr Patrik Frei
Dr Patrik Frei
CEO 

Wellington Partners Germany

Wellington Partners is a venture capital firm based in Munich, Germany, with an additional office in Zurich, Switzerland. The firm specializes in early-stage and growth capital investments in the Technology and Life Sciences sector. The firm has approximately €800M AUM and is currently investing out of a €100M fund for Life Science companies. Depending on the stage of the company, the firm can allocate up to €10M over the life of the investment. The firm can also lead or co-lead financing rounds of up to €30M or higher with syndicates. The firm focuses on European companies but will consider US-based companies with activities in Europe. The firm is actively seeking new investment opportunities.

Year Founded
1990
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Rainer Strohmenger
General Partner 

Westwood & Wilshire LLC United States

Westwood & Wilshire is a premier provider of executive search services to the Pharmaceutical, Biotechnology, Medical Devices and Diagnostics sectors.  Services include:

-Direct Hire Executive Search
-Interim Executive Search and Consultant Placement
-Board of Director and Advisory Group Development

Our clients range from Venture Capital-backed portfolio start ups to Fortune 500 Big Pharma. Our success encompasses executive level placements across Clinical, Medical, Regulatory, R&D, Quality and Commercial.

Alan Cullen
President 
Michael Cane
Executive Recruiter